ACP
SVA

Acuta Capital Partners’s Sinovac Biotech, Ltd SVA Stock Holding History

Acuta Capital Partners’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-204,358
Closed -$1.21M – 83
2016
Q3 		$1.21M Buy
204,358
+71,855
+54% +$423K 0.45% 43
2016
Q2 		$786K Buy
+132,503
New +$812K 0.38% 48

Other funds holding SVA

SA
SAIF Advisors Admiralty, Hong Kong $438M AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $1.24B AUM 2.91% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $359M AUM 23.01% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

Acuta Capital Partners's SVA Position: Q4 2016 in Review

Acuta Capital Partners sold out of Sinovac Biotech, Ltd (SVA) in Q4 2016, closing a stake of 204,358 shares — an estimated $1.21M sold.

Acuta Capital Partners first reported a position in SVA in Q2 2016 and held it in 2 quarters. The position peaked at $1.21M in Q3 2016. 38 funds tracked by Wall St. Rank hold SVA as of Q4 2016.

  • Acuta Capital Partners reported no remaining Sinovac Biotech, Ltd position as of Q4 2016 after selling out during the quarter.
  • Acuta Capital Partners sold 204,358 Sinovac Biotech, Ltd shares in Q4 2016, an estimated $1.21M.
  • Acuta Capital Partners first reported a position in Sinovac Biotech, Ltd in Q2 2016 and held it in 2 quarters.
  • Acuta Capital Partners's Sinovac Biotech, Ltd position peaked at $1.21M in Q3 2016.
  • 38 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q4 2016.

Based on Acuta Capital Partners's 13F filing for Q4 2016, filed 13 Feb 2017.